Capsid integrity RT-qPCR for the selective detection of intact SARS-CoV-2 in wastewater폐수에서 온전한 SARS-CoV-2의 선택적 검출을 위한 캡시드 무결성 RT-qPCRArticle Published on 2021-10-152022-09-11 Journal: The Science of the total environment [Category] SARS, 치료기술, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus applicability Area biosafety level Biosafety Level 3 capsid Capsid integrity RT-qPCR collected Concentration Concentration method coronavirus determine determined by Effect EMA evaluated form Genome genomes glycol heat-inactivated IMPROVE intact virus Interpretation investigated level 3 MHV murine hepatitis virus PMA Polyethylene glycol positive positive result positive sample qPCR reagents RT-qPCR SARS-CoV-2 selective severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 surrogate tested Tokyo Ultrafiltration virus was used wastewater [DOI] 10.1016/j.scitotenv.2021.148342 PMC 바로가기 [Article Type] Article
A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report렘데시비르 또는 하이드록시클로로퀸으로 치료받은 COVID-19 환자의 약물 부작용을 평가하기 위한 전향적 관찰 연구: 예비 보고서Observational Study Published on 2021-09-012022-09-11 Journal: European Journal of Hospital Pharmacy [Category] 임상, 치료제, [키워드] activity acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 ADR ADRS Adverse drug reaction Adverse drug reactions adverse effect Adverse reactions authorisation baseline characteristics carried Causality clinical medicine Cohort cohorts coronavirus disease Coronavirus disease 2019 Coronavirus-2 COVID-19 cumulative drug monitoring drug-related side effects and adverse reactions Efficacy EMA European Medicines Agency evaluate greater HCQ Health authority hospital hospitalised Hydroxychloroquine implementation incidence Local Observational cohort study outbreak participant Patient patients patients with COVID-19 pharmacovigilance pharmacy service preliminary report pressure public health real-world data regimen REM Remdesivir reported safety profile SARS-CoV-2 Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Side effect Side effects study period Suspected System Therapeutic strategies treated Treatment treatment of COVID-19 [DOI] 10.1136/ejhpharm-2020-002613 PMC 바로가기 [Article Type] Observational Study
Mathematical Modeling of Remdesivir to Treat COVID-19: Can Dosing Be Optimized?Article Published on 2021-07-312022-10-28 Journal: Pharmaceutics [Category] COVID-19, [키워드] active form administration Antiviral antivirals approved Can cell entry clinical trial complicate COVID-19 Dosing dosing regimen drug Drug efficacy Efficacy EMA European Medicines Agency FDA food help identify inhibit limit Lungs modeling morbidity parameter PK/PD model polymerase reduce regimen Regulatory Remdesivir resistant mutant SARS-CoV-2 Strains suppress the binding affinity therapeutic Toxicity Treatment while wild-type [DOI] 10.3390/pharmaceutics13081181 PMC 바로가기 [Article Type] Article
COVID-19 Vaccines and Thrombosis—Roadblock or Dead-End Street?Covid-19 백신 및 혈전증-로드 블록 또는 막 다른 거리?Review Published on 2021-07-132022-09-10 Journal: Biomolecules [Category] SARS, 변종, 유전자 메커니즘, [키워드] Ad26 Ad26.COV2.S addition Adenovirus adenovirus-based adverse effect antibodies approved BNT162b2 cause causes CD147 CD46 cellular ChAdOx1 ChAdOx1 nCoV-19 chronic smokers coronavirus coronavirus disease coronavirus disease-2019 COV2.S COVID-19 elicited EMA European Medicines Agency event Frequency Genetic groups heparan sulfate immune immunological mechanism in some incidence individual Interaction low frequency mRNA-based vaccines Platelet platelet factor 4 Proteoglycan recent receptor receptors reducing reported risk SARS-CoV-2 SARS-CoV-2 spike protein Smokers Spike protein splice sulfate the spike protein thrombocytopenia thrombosis thrombotic Thrombotic thrombocytopenia vaccination vaccine administration Vaccines variant Viral viral disease Viral diseases Viral vector viral vectors [DOI] 10.3390/biom11071020 PMC 바로가기 [Article Type] Review
Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitro메틸렌 블루는 시험 관내 UV- 활성화의 부재하에 SARS-COV-2 및 H1N1 인플루엔자 바이러스에 대한 강력한 항 바이러스 활성을 갖는다.Article Published on 2021-07-122022-09-01 Journal: Scientific Reports [Category] SARS, 유전자 메커니즘, 진단, 치료제, [키워드] absence Activation addition antiviral activity Antiviral agents approved blood product blood products blue Cell Clinical studies clinical study Concentration Degradation drug effective EMA European Medicines Agency evaluated examined FDA food genomic RNA H1N1 H1N1 influenza immune Immune Serum in vitro infected with SARS-CoV-2 Influenza influenza virus H1N1 malaria mechanism methemoglobinemia Methylene Methylene blue presence or absence safety profile SARS-CoV-2 SARS-CoV-2 infections serum shown Support therapeutic activity therapeutic efficacy Treatment UV light viral infection virucidal virus viruses [DOI] 10.1038/s41598-021-92481-9 PMC 바로가기 [Article Type] Article
Corona Health—A Study- and Sensor-Based Mobile App Platform Exploring Aspects of the COVID-19 PandemicArticle Published on 2021-07-102022-10-29 Journal: International Journal of Environmental Research an [Category] COVID-19, SARS, [키워드] alleviate Apple aspect changes in Collaborative effort collected collected data Combination Corona Course COVID-19 COVID-19 pandemic Digital phenotyping ecological momentary assessment eight EMA FIVE Google Play Health help Implementing IMPROVE knowledge Longitudinal studies longitudinal study Measures Mental Mobile mobile crowdsensing Mobile health pandemic physical platform protective factor public health questionnaire recall bias Regulatory released Research risk trajectory [DOI] 10.3390/ijerph18147395 PMC 바로가기 [Article Type] Article
Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label규제 결정에 대한 대중의 신뢰: 유럽 의약품청 및 AstraZeneca COVID-19 백신 라벨Article Published on 2021-07-052022-09-11 Journal: Vaccine [Category] SARS, 신약개발, [키워드] Abstract Adults AstraZeneca AstraZeneca vaccine Conditional marketing authorization COVID-19 COVID-19 vaccine elderly EMA European Medicines Agency Older adults Public Regulatory [DOI] 10.1016/j.vaccine.2021.05.095 PMC 바로가기 [Article Type] Article
The Safety of COVID-19 Vaccinations—We Should Rethink the PolicyArticle Published on 2021-06-242022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] 95% confidence interval Adverse Adverse drug reaction Adverse reaction benefit calculated COVID-19 COVID-19 vaccine database death drug EMA European Medicines Agency fatal side effects Government lack mRNA vaccine mRNA-vaccine number needed to vaccinate Pfizer Policy Prevent prevented reaction reported Result risk Safety SARS-CoV2 Side effect Side effects vaccinate vaccination Vaccinations [DOI] 10.3390/vaccines9070693 PMC 바로가기 [Article Type] Article
Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU StatesArticle Published on 2021-06-182022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] affected age AstraZeneca AZD1222 benefit Blood carried ChAdOx1 nCoV-19 chill chronic Chronic illness composed COVID-19 COVID-19 vaccine cross-sectional Czech Republic Demographic variables disorder drug-related side effects and adverse reactions EMA European Medicines Agency evaluate Evidence fatigue female Frequency Gender Germany headache Health personnel healthcare worker illness incidence increased risk independent Infection injection site pain Local majority mass vaccination medical treatment medical treatments nausea Oxford–AstraZeneca vaccine Pain participant Participants potential risk Prevalence questionnaire receiving recent reported required resolved Safety Side effect state supported the vaccine thrombosis urgent investigation Vaccine [DOI] 10.3390/vaccines9060673 PMC 바로가기 [Article Type] Article
SARS‐CoV‐2 and hypertensionReview Published on 2021-06-132022-10-28 Journal: Physiological Reports [Category] COVID-19, MERS, SARS, [키워드] ACE2 ACE2 expression acute respiratory syndrome approved biological processe caused clinical trial Coronary artery disease coronavirus COVID‐19 COVID‐19 infection COVID‐19 death disease downregulation drug dysregulation Effect EMA enzyme fatality FDA function heart failure host cell hypertension knowledge MAS‐receptor mechanism multifactorial pathophysiological Prophylaxis Protein public health RAAS receptor reducing regulated Regulatory renin–angiotensin–aldosterone system Research risk factor SARS‐CoV‐2 SARS‐CoV‐2 severity stroke System tested Treatment Vaccine [DOI] 10.14814/phy2.14800 PMC 바로가기 [Article Type] Review